O 6 -methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies

Table 2 Diagnosis and p53 status of human gliomas: The index of Ki-67 staining and p53 status (mutation and immunopositivity) are listed with patient ID, age at surgery, gender (F, female; M, male), and clinical diagnosis (GBM, glioblastoma, WHO grade IV; AA, anaplastic astrocytoma, WHO grade III, AE anaplastic ependymoma, WHO grade III). Images of H&E staining and immunohistochemistry are shown [see additional file 1].

ID	Age	Gender	Diagnosis	Ki-67 (%) ^a	p53 mutations ^b	p53 staining ^c
G1	73	F	GBM	4.0	N	+
G2	58	M	GBM	44.3	R156P, H214R	++
G3	36	M	GBM	24.8	N	-
G4	77	F	GBM	92.5	N	-
G5	53	M	GBM	12.6	N	++
G6	61	M	GBM	43.6	N	+
G7	83	M	GBM	53.1	H193P	++
G8	28	M	GBM	29.0	H214R	+++
G9	55	F	AA	3.3	N	+++
G10	42	F	AE	42.6	N	-

^aMIB-1 labeling index (by anti-Ki-67 antibody) was analyzed using the MetaMorphV7.0 software (Molecular Cevices, Downingtown, PA, USA), by counting 500–2,000 nuclei per case.
^bp53 cDNA was amplified by RT-PCR and the products were directly sequenced. N, no mutation was detected.
^cStaining intensity was classified into four categories: +++, strong; ++, moderate; +, weak; -, negative.

ISSN: 1476-4598